https://pepsreview.com/articles/semaglutide-resmetirom-mash-indirect-comparison-weight-loss PepsReview en 2026-11-07 semaglutide, resmetirom, MASH, MASH treatment comparison, ESSENCE trial, MAESTRO-NASH, GLP-1 liver disease, MASH fibrosis https://pepsreview.com/articles/fda-28-day-vial-rule-glp1-api-border-alert PepsReview en 2026-11-07 compounded GLP-1, FDA guidance, multi-dose vial, retatrutide, cagrilintide, import alert 66-80, peptide testing https://pepsreview.com/articles/lilly-nad-good-life-compounded-tirzepatide-claims PepsReview en 2026-11-06 compounded tirzepatide, Eli Lilly, National Advertising Division, Good Life Meds, GLP-1 enforcement, peptide regulation, telehealth weight loss https://pepsreview.com/articles/clinicians-push-back-six-unapproved-peptides-compounding-policy PepsReview en 2026-11-06 peptide compounding, BPC-157, TB-500, FDA enforcement discretion, unapproved peptides, peptide safety, compounded peptides, HHS peptide policy https://pepsreview.com/articles/lilly-mevidalen-alzheimer-phase-2-pipeline-removal PepsReview en 2026-11-06 mevidalen, Eli Lilly Alzheimer's, dopamine D1 PAM, phase 2 Alzheimer's trial, peptide research, CNS drug development, neuroscience pipeline https://pepsreview.com/articles/tirzepatide-high-dose-semaglutide-indirect-comparison-4-5-points PepsReview en 2026-11-06 tirzepatide, semaglutide, Zepbound, Wegovy HD, indirect treatment comparison, SURMOUNT-5, GLP-1 obesity trials, peptide evidence https://pepsreview.com/articles/novo-third-outlook-raise-wegovy-pill-rollout-q3-2026 PepsReview en 2026-11-06 Novo Nordisk, Wegovy pill, oral semaglutide, GLP-1 market, obesity drugs, Eli Lilly, peptide supply, GLP-1 pricing